RA PHARMCTL INC (RARX)
(Delayed Data from NSDQ)
$21.94 USD
-0.22 (-0.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $21.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.94 USD
-0.22 (-0.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $21.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RARX) Outperforming Other Medical Stocks This Year?
How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Ra Pharmaceuticals (RARX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug
by Zacks Equity Research
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
Company News For Oct 11, 2019
by Zacks Equity Research
Companies in the news are: RARX, BBBY, PCG, MITO
Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
by Zacks Equity Research
Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?
by Zacks Equity Research
Ra Pharmaceuticals, Inc. (RARX) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA.
RA PHARMCTL INC (RARX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
RA PHARMCTL has been struggling lately, but the selling pressure may be coming to an end soon.